DE69839529D1 - Expressionsvektoren und zellinien zur expression von vaskulärem wachstumsfaktor d, sowie verfahren zur behandlung von melanomen - Google Patents

Expressionsvektoren und zellinien zur expression von vaskulärem wachstumsfaktor d, sowie verfahren zur behandlung von melanomen

Info

Publication number
DE69839529D1
DE69839529D1 DE69839529T DE69839529T DE69839529D1 DE 69839529 D1 DE69839529 D1 DE 69839529D1 DE 69839529 T DE69839529 T DE 69839529T DE 69839529 T DE69839529 T DE 69839529T DE 69839529 D1 DE69839529 D1 DE 69839529D1
Authority
DE
Germany
Prior art keywords
growth factor
cell lines
expression vectors
vascular growth
treating melanoma
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE69839529T
Other languages
English (en)
Inventor
Marc G Achen
Steven Alan Stacker
Kari Alitalo
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
VEGENICS LTD., TOORAK, VICTORIA, AU
Original Assignee
Ludwig Institute for Cancer Research Ltd
Ludwig Institute for Cancer Research New York
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from AUPP1131A external-priority patent/AUPP113197A0/en
Application filed by Ludwig Institute for Cancer Research Ltd, Ludwig Institute for Cancer Research New York filed Critical Ludwig Institute for Cancer Research Ltd
Application granted granted Critical
Publication of DE69839529D1 publication Critical patent/DE69839529D1/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A61K38/1858—Platelet-derived growth factor [PDGF]
    • A61K38/1866—Vascular endothelial growth factor [VEGF]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/22—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Immunology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Dermatology (AREA)
  • Epidemiology (AREA)
  • Toxicology (AREA)
  • Vascular Medicine (AREA)
  • Cardiology (AREA)
  • Diabetes (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Hematology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
DE69839529T 1997-12-24 1998-12-23 Expressionsvektoren und zellinien zur expression von vaskulärem wachstumsfaktor d, sowie verfahren zur behandlung von melanomen Expired - Lifetime DE69839529D1 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
AUPP1131A AUPP113197A0 (en) 1997-12-24 1997-12-24 Growth factor
US8739298P 1998-05-29 1998-05-29
PCT/US1998/027373 WO1999033485A1 (en) 1997-12-24 1998-12-23 Expression vectors and cell lines expressing vascular endothelial growth factor d, and method of treating melanomas

Publications (1)

Publication Number Publication Date
DE69839529D1 true DE69839529D1 (de) 2008-07-03

Family

ID=25645688

Family Applications (1)

Application Number Title Priority Date Filing Date
DE69839529T Expired - Lifetime DE69839529D1 (de) 1997-12-24 1998-12-23 Expressionsvektoren und zellinien zur expression von vaskulärem wachstumsfaktor d, sowie verfahren zur behandlung von melanomen

Country Status (10)

Country Link
US (4) US7947472B2 (de)
EP (1) EP1054687B8 (de)
JP (2) JP2003517265A (de)
KR (1) KR100628697B1 (de)
CN (1) CN1345247A (de)
AT (1) ATE395928T1 (de)
CA (1) CA2315977A1 (de)
DE (1) DE69839529D1 (de)
NZ (1) NZ505011A (de)
WO (1) WO1999033485A1 (de)

Families Citing this family (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6824777B1 (en) 1992-10-09 2004-11-30 Licentia Ltd. Flt4 (VEGFR-3) as a target for tumor imaging and anti-tumor therapy
DK0956339T3 (da) 1996-08-23 2006-01-30 Licentia Oy Rekombinant vaskulær endotelcellevækstfaktor D (VEGF-D)
US7125714B2 (en) 1997-02-05 2006-10-24 Licentia Ltd. Progenitor cell materials and methods
DE69839529D1 (de) 1997-12-24 2008-07-03 Ludwig Inst Cancer Res Expressionsvektoren und zellinien zur expression von vaskulärem wachstumsfaktor d, sowie verfahren zur behandlung von melanomen
CA2345276C (en) 1998-10-09 2011-03-29 Ludwig Institute For Cancer Research Flt4 (vegfr-3) as a target for tumor imaging and anti-tumor therapy
CN1330555A (zh) 1998-12-21 2002-01-09 路德维格癌症研究所 抗截短的vegf－d的抗体及其应用
AU2001227717A1 (en) * 2000-01-11 2001-07-24 Stephen E Epstein Enhancing lymph channel development and treatment of lymphatic obstructive disease
DE60131146T2 (de) * 2000-02-25 2008-03-06 Ludwig Institute For Cancer Research Material und verfahren die hybridvaskularendothelwachstumfaktoren dns und proteine enthalten und screeningverfahren für modulatoren
US20020102260A1 (en) * 2000-03-02 2002-08-01 Marc Achen Methods for treating neoplastic disease characterized by vascular endothelial growth factor D expression, for screening for neoplastic disease or metastatic risk, and for maintaining vascularization of tissue
DK1259248T3 (da) * 2000-03-02 2005-04-11 Ludwig Inst Cancer Res Fremgangsmåde til behandling af cancere, der udtrykker vaskulær endotelvækstfaktor D
AU2006201128B2 (en) * 2000-03-02 2009-05-28 Vegenics Limited Methods for treating, screening for, and detecting cancers expressing vascular endothelial growth factor D
WO2001064235A1 (en) * 2000-03-02 2001-09-07 Ludwig Institute For Cancer Research Methods for treating, screening for, and detecting cancers expressing vascular endothelial growth factor d
AU6456501A (en) * 2000-05-03 2001-11-12 Ludwig Inst Cancer Res A method for activating only the vascular endothelial growth factor receptor-3 and uses thereof
WO2002029087A2 (en) * 2000-10-02 2002-04-11 St. Elizabeth's Medical Center Of Boston, Inc. Use of lymphangiogenic agents to treat lymphatic disorders
AU2884102A (en) 2000-12-07 2002-06-18 Sangamo Biosciences Inc Regulation of angiogenesis with zinc finger proteins
US7067317B2 (en) 2000-12-07 2006-06-27 Sangamo Biosciences, Inc. Regulation of angiogenesis with zinc finger proteins
US7611711B2 (en) 2001-01-17 2009-11-03 Vegenics Limited VEGFR-3 inhibitor materials and methods
JP4669984B2 (ja) * 2001-01-19 2011-04-13 ベジェニクス リミテッド 腫瘍画像化のターゲットとしてのＦ１ｔ４（ＶＥＧＦＲ−３）および抗腫瘍療法
AR027161A1 (es) * 2001-05-15 2003-03-19 Bio Sidus S A Metodo para inducir la proliferacion neovascular y regeneracion tisular
WO2003006104A2 (en) * 2001-07-12 2003-01-23 Ludwig Institute For Cancer Research Lymphatic endothelial cells materials and methods
US20030113324A1 (en) * 2001-10-01 2003-06-19 Kari Alitalo Neuropilin/VEGF-C/VEGFR-3 materials and methods
US20040214766A1 (en) * 2001-10-01 2004-10-28 Kari Alitalo VEGF-C or VEGF-D materials and methods for treatment of neuropathologies
AUPS051002A0 (en) * 2002-02-14 2002-03-07 Riancorp Pty Ltd Low level laser therapy method and means
ITRM20020119A1 (it) * 2002-03-05 2003-09-05 Geymonat Spa Composizioni contenenti plgf ad uso farmaceutico e cosmetico.
US20030228283A1 (en) * 2002-05-03 2003-12-11 Ludwig Institute For Cancer Research Preventing secondary lymphedema with VEGF-D DNA
CN1327000C (zh) * 2002-09-06 2007-07-18 中国人民解放军军事医学科学院基础医学研究所 靶向黑色素瘤的可复制性腺病毒穿梭载体及腺病毒
ES2744275T3 (es) 2002-10-17 2020-02-24 Genmab As Anticuerpos monoclonales humanos contra CD20 para su uso en el tratamiento de esclerosis múltiple
AU2004209668A1 (en) * 2003-02-04 2004-08-19 Flanders Interuniversity Institute For Biotechnology VEGF-B and PDGF modulation of stem cells
WO2005011722A2 (en) * 2003-06-12 2005-02-10 Ludwig Institute For Cancer Research Use of vegf-c or vegf-d in reconstructive surgery
US20050032697A1 (en) * 2003-06-12 2005-02-10 Kari Alitalo Heparin binding VEGFR-3 ligands
US7850962B2 (en) 2004-04-20 2010-12-14 Genmab A/S Human monoclonal antibodies against CD20
EP1869075B1 (de) 2005-02-28 2012-04-11 Sangamo BioSciences, Inc. Antiangiogene methoden und zusammensetzungen
ES2363758T3 (es) * 2005-08-15 2011-08-16 Vegenics Pty Ltd Vegf y pdgf modificados con propiedades angiogénicas mejoradas.
US20080267924A1 (en) * 2007-02-07 2008-10-30 Vegenics Limited Autologous lymph node transfer in combination with vegf-c or vegf-d growth factor therapy to treat secondary lymphedema and to improve reconstructive surgery
US20110305703A1 (en) * 2008-12-08 2011-12-15 Vegenics Pty Limited Isolated vegf-c and vegf-d peptides and uses thereof
WO2012088563A1 (en) * 2010-11-24 2012-07-05 Vegenics Pty Limited Vegfr-2-specific forms of vegf-d and vegf-c and uses thereof
EP3693381A1 (de) 2013-02-18 2020-08-12 Vegenics Pty Limited Ligandbindende moleküle und verwendungen davon

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4851341A (en) * 1986-12-19 1989-07-25 Immunex Corporation Immunoaffinity purification system
US5179426A (en) * 1987-08-04 1993-01-12 Seiko Epson Corporation Josephson device
US5179007A (en) * 1989-07-07 1993-01-12 The Texas A & M University System Method and vector for the purification of foreign proteins
US5194596A (en) * 1989-07-27 1993-03-16 California Biotechnology Inc. Production of vascular endothelial cell growth factor
US6107046A (en) * 1992-10-09 2000-08-22 Orion Corporation Antibodies to Flt4, a receptor tyrosine kinase and uses thereof
US6824777B1 (en) * 1992-10-09 2004-11-30 Licentia Ltd. Flt4 (VEGFR-3) as a target for tumor imaging and anti-tumor therapy
DE69434538T2 (de) * 1994-03-08 2006-08-10 Human Genome Sciences, Inc. Vaskulärer endothelialer Wachstumsfaktor 2
EP1553182B1 (de) * 1995-09-29 2010-03-03 Universita Degli Studi Di Siena Regulierte Gene und ihre Verwendungen
US5792850A (en) * 1996-05-23 1998-08-11 Zymogenetics, Inc. Hematopoietic cytokine receptor
US6828426B1 (en) * 1996-07-15 2004-12-07 Chugai Seiyaku Kabushiki Kaisha VEGF-like factor
DK0956339T3 (da) * 1996-08-23 2006-01-30 Licentia Oy Rekombinant vaskulær endotelcellevækstfaktor D (VEGF-D)
WO1998024811A2 (en) 1996-12-06 1998-06-11 Zymogenetics, Inc. Vascular endothelial growth factor
DE69839529D1 (de) * 1997-12-24 2008-07-03 Ludwig Inst Cancer Res Expressionsvektoren und zellinien zur expression von vaskulärem wachstumsfaktor d, sowie verfahren zur behandlung von melanomen
WO2005011722A2 (en) * 2003-06-12 2005-02-10 Ludwig Institute For Cancer Research Use of vegf-c or vegf-d in reconstructive surgery
US6889580B1 (en) * 2004-04-19 2005-05-10 A.A.G. Industrial Co., Ltd. Socket for adapting itself to open ends of wrenches of different sizes

Also Published As

Publication number Publication date
WO1999033485A1 (en) 1999-07-08
CN1345247A (zh) 2002-04-17
JP2009159972A (ja) 2009-07-23
US20020127222A1 (en) 2002-09-12
US7947472B2 (en) 2011-05-24
KR100628697B1 (ko) 2006-09-28
KR20010033537A (ko) 2001-04-25
NZ505011A (en) 2004-12-24
JP2003517265A (ja) 2003-05-27
US20110059890A1 (en) 2011-03-10
US20120270781A1 (en) 2012-10-25
ATE395928T1 (de) 2008-06-15
US8461109B2 (en) 2013-06-11
EP1054687A1 (de) 2000-11-29
US20110269146A1 (en) 2011-11-03
EP1054687A4 (de) 2004-06-09
EP1054687B8 (de) 2008-07-16
EP1054687B1 (de) 2008-05-21
CA2315977A1 (en) 1999-07-08

Similar Documents

Publication Publication Date Title
DE69839529D1 (de) Expressionsvektoren und zellinien zur expression von vaskulärem wachstumsfaktor d, sowie verfahren zur behandlung von melanomen
DK1100529T4 (da) Thymosin beta 4 fremmer sårheling
DE69736197D1 (de) Antikoagulierende humanisierte Antikörper gegen Faktor IX, zur Verwendung in der Behandlung von Thrombose
DE69827001D1 (de) Gewebedezellularization
DE69010893T2 (de) Verfahren zur behandlung von koks sowie löschen desselben.
DE69838338D1 (de) Verwendung von antimykotica zur topischen behandlung von pilz-induzierten schleimhautentzündungen
DE69523074D1 (de) Verfahren zur behandlung von implantierbaren biologischen geweben zur verringerung von verkalkung
DE69435096D1 (de) Zusammensetzung zur in vivo erzeugung von therapeutischen produkten
MY102505A (en) Novel osteoinductive factors.
DE69527847T2 (de) Verwendung von anti-vegf-mitteln zur behandlung der endometriose
DE3578611D1 (de) Instrumente zur behandlung von verformten naegeln bei menschlichen patienten.
ATE253934T1 (de) Verwendung eines angiogenen faktors zur behandlung von mikrovaskulären angiopathien
DE68917433T2 (de) Verfahren zur behandlung von asbest sowie asbestbehandlungsmittel.
DE69734464D1 (de) Verfahren zur expression und herstellung von rekombinantem, menschlichem beta-cis-interferon
DE69626311D1 (de) Zusammensetzung zur behandlung von wäsche sowie verfahren hierfür
DE69818809D1 (de) Verfahren zur behandlung von narbengewebe
DE59508509D1 (de) Dna-expressionsvektoren zur verwendung in der gentherapeutischen behandlung von gefässerkrankungen
DE69626816D1 (de) Verwendung von selegilin zur behandlung von gehörverlust bei säugetieren
EP0159446A3 (de) Kosmetische Kopfhautbehandlung
DE69920015D1 (de) Verfahren zur induktion der herstellung von wachstumsfaktoren
EP0967276A3 (de) Antitumor-Mittel dass Salmosin enthält
DE59100212D1 (de) Verfahren zur verformenden behandlung von keratinfasern sowie mittel zur durchfuehrung des verfahrens.
ATE209042T1 (de) Verwendung des wachstumshormons in mitteln zur behandlung der insulinresistenz im herzen
ATE222501T1 (de) Tissue-faktor zur beeinflussung von gefässbildung
ATE306278T1 (de) Behandlung von knochenleiden mit adrenomedullin

Legal Events

Date Code Title Description
8327 Change in the person/name/address of the patent owner

Owner name: VEGENICS LTD., TOORAK, VICTORIA, AU

8364 No opposition during term of opposition